Mehdi Mousavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mehdi Mousavi has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Hamidreza Poorhosseini
From the Tehran University of Medical Sciences, Tehran, Iran
3 shared publicationsSeyed Ebrahim Kassaian
From the Tehran University of Medical Sciences, Tehran, Iran
3 shared publicationsAlimohammad Hajizeinali
From the Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsAlireza Amirzadegan
From the Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsEbrahim Nematipour
From the Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsMohammad Alidoosti
From the Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 28 May 2024
- Published by BMJ in Family Medicine and Community Health
- Vol. 12 (Suppl 1) , e002626
Performance of generative pre-trained transformers (GPTs) in Certification Examination of the College of Family Physicians of Canada
Introduction The application of large language models such as generative pre-trained transformers (GPTs) has been promising in medical education, and its performance has been tested for different medical exams. This study aims to assess the performance of GPTs in responding to a set of sample questions of short-answer management problems (SAMPs) from the certification exam of the College of Family Physicians of Canada (CFPC). Method Between August 8th and 25th, 2023, we used GPT-3.5 and GPT-4 in five rounds to answer a sample of 77 SAMPs questions from the CFPC website. Two independent certified family physician reviewers scored AI-generated responses twice: first, according to the CFPC answer key (ie, CFPC score), and second, based on their knowledge and other references (ie, Reviews’ score). An ordinal logistic generalised estimating equations (GEE) model was applied to analyse repeated measures across the five rounds. Result According to the CFPC answer key, 607 (73.6%) lines of answers by GPT-3.5 and 691 (81%) by GPT-4 were deemed accurate. Reviewer’s scoring suggested that about 84% of the lines of answers provided by GPT-3.5 and 93% of GPT-4 were correct. The GEE analysis confirmed that over five rounds, the likelihood of achieving a higher CFPC Score Percentage for GPT-4 was 2.31 times more than GPT-3.5 (OR: 2.31; 95% CI: 1.53 to 3.47; pConclusion In our study, we used GPT-3.5 and GPT-4 to answer complex, open-ended sample questions of the CFPC exam and showed that more than 70% of the answers were accurate, and GPT-4 outperformed GPT-3.5 in responding to the questions. Large language models such as GPTs seem promising for assisting candidates of the CFPC exam by providing potential answers. However, their use for family medicine education and exam preparation needs further studies.
- 28 May 2024
- Published by BMJ in Family Medicine and Community Health
- Vol. 12 (Suppl 1) , e002626
Open AccessPerformance of generative pre-trained transformers (GPTs) in Certification Examination of the College of Family Physicians of Canada
Introduction The application of large language models such as generative pre-trained transformers (GPTs) has been promising in medical education, and its performance has been tested for different medical exams. This study aims to assess the performance of GPTs in responding to a set of sample questions of short-answer management problems (SAMPs) from the certification exam of the College of Family Physicians of Canada (CFPC). Method Between August 8th and 25th, 2023, we used GPT-3.5 and GPT-4 in five rounds to answer a sample of 77 SAMPs questions from the CFPC website. Two independent certified family physician reviewers scored AI-generated responses twice: first, according to the CFPC answer key (ie, CFPC score), and second, based on their knowledge and other references (ie, Reviews’ score). An ordinal logistic generalised estimating equations (GEE) model was applied to analyse repeated measures across the five rounds. Result According to the CFPC answer key, 607 (73.6%) lines of answers by GPT-3.5 and 691 (81%) by GPT-4 were deemed accurate. Reviewer’s scoring suggested that about 84% of the lines of answers provided by GPT-3.5 and 93% of GPT-4 were correct. The GEE analysis confirmed that over five rounds, the likelihood of achieving a higher CFPC Score Percentage for GPT-4 was 2.31 times more than GPT-3.5 (OR: 2.31; 95% CI: 1.53 to 3.47; pConclusion In our study, we used GPT-3.5 and GPT-4 to answer complex, open-ended sample questions of the CFPC exam and showed that more than 70% of the answers were accurate, and GPT-4 outperformed GPT-3.5 in responding to the questions. Large language models such as GPTs seem promising for assisting candidates of the CFPC exam by providing potential answers. However, their use for family medicine education and exam preparation needs further studies.
- 30 January 2023
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 51, 1-7
A Double-Blinded Randomized Controlled Trial Comparing Eptifibatide Bolus Only Versus Bolus Plus Infusion In Patients Undergoing Primary Percutaneous Coronary Intervention For ST-Elevation Myocardial Infarction
- 30 January 2023
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 51, 1-7
A Double-Blinded Randomized Controlled Trial Comparing Eptifibatide Bolus Only Versus Bolus Plus Infusion In Patients Undergoing Primary Percutaneous Coronary Intervention For ST-Elevation Myocardial Infarction
- Open Access
- 28 September 2021
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 14 (5) , 119-124
Comparison of heart rate and symptoms in two different methods of digoxin prescription
Background:Medication interruption of two days a week is common in Iran to avoid the toxic effects of digoxin; however, the efficacy on symptoms and heart rate is not well studied yet. Methods: The current clinical trial was conducted on patients receiving a digoxin regimen of 0.125mg/day or 0.25 mg/day except for Mondays and Fridays (0.25mg/day-5/7) for atrial fibrillation (AF) or heart failure (HF). After measuring digoxin level and heart rate and scoring the clinical symptoms, the enrolled patients were switched to another method of digoxin prescription. The symptoms were reevaluated after four weeks of changing the regimen of digoxin. The study was registered in the Iranian Registry of Clinical Trials (IRCT) (No. 20110512006463N2). Results: A total of 77 patients completed the study. The mean age of the enrolled group was 65.16±11.64 years, and 44 patients (55.7%) were female. The mean digoxin level was 0.76±0.35 in the 0.125mg/day regimen, which changed to 0.94±0.56 in the 0.25mg/day-5/7 regimen (P=0.034). Heart rate (HR) and daily activity scores, pain, spiritual feelings, energy, dyspnea, palpitation, nausea, blurred vision, and quality of life did not show any significant changes in the two regimens. The results of subgroup analysis in patients with AF were similar in terms of HR and symptoms, while in the subjects without AF, the scores of daily activity, dyspnea, palpitation, and quality of life significantly improved with the 0.25mg/day-5/7 regimen. Conclusions: Results of the current study showed that the HR and symptoms were not considerably different in the two regimens, whereas the digoxin level was significantly higher in the 0.25mg/day-5/7 regimen. Furthermore, in the subgroup with HF but without AF, the 0.25mg/day-5/7 regimen offered a better symptom control of dyspnea, palpitation, daily activity, and quality of life.
- 28 September 2021
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 14 (5) , 119-124
Open AccessComparison of heart rate and symptoms in two different methods of digoxin prescription
Background:Medication interruption of two days a week is common in Iran to avoid the toxic effects of digoxin; however, the efficacy on symptoms and heart rate is not well studied yet. Methods: The current clinical trial was conducted on patients receiving a digoxin regimen of 0.125mg/day or 0.25 mg/day except for Mondays and Fridays (0.25mg/day-5/7) for atrial fibrillation (AF) or heart failure (HF). After measuring digoxin level and heart rate and scoring the clinical symptoms, the enrolled patients were switched to another method of digoxin prescription. The symptoms were reevaluated after four weeks of changing the regimen of digoxin. The study was registered in the Iranian Registry of Clinical Trials (IRCT) (No. 20110512006463N2). Results: A total of 77 patients completed the study. The mean age of the enrolled group was 65.16±11.64 years, and 44 patients (55.7%) were female. The mean digoxin level was 0.76±0.35 in the 0.125mg/day regimen, which changed to 0.94±0.56 in the 0.25mg/day-5/7 regimen (P=0.034). Heart rate (HR) and daily activity scores, pain, spiritual feelings, energy, dyspnea, palpitation, nausea, blurred vision, and quality of life did not show any significant changes in the two regimens. The results of subgroup analysis in patients with AF were similar in terms of HR and symptoms, while in the subjects without AF, the scores of daily activity, dyspnea, palpitation, and quality of life significantly improved with the 0.25mg/day-5/7 regimen. Conclusions: Results of the current study showed that the HR and symptoms were not considerably different in the two regimens, whereas the digoxin level was significantly higher in the 0.25mg/day-5/7 regimen. Furthermore, in the subgroup with HF but without AF, the 0.25mg/day-5/7 regimen offered a better symptom control of dyspnea, palpitation, daily activity, and quality of life.
- 1 March 2019
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 18 (1) , 23-31
Effect of Age on Procedural Success, Complications, and Clinical Outcome From a Large Angioplasty Registry
Increasing age appears to be a risk factor for adverse outcome in patients undergoing percutaneous coronary intervention (PCI). The goal of this study was to compare procedural success, complications, and 12 months major adverse cardiac events (MACE) based on age using a large angioplasty registry. This registry included 10,412 patients with at least 12-month follow-up from April 1993 to April 2011. Patients were divided into 3 age groups: group 1 age < 60 (n = 6195), group 2 age 60–75 (n = 3724) and group 3 elderly age ≥ 75 (n = 493). Procedural success rate was not significantly different across the 3 age groups. (96.9% in group 1, 97.1% in group 2, and 96.1% in elderly group, P = 0.759). Procedural complications occurred in 179 (2.9%) of group 1, 98 (2.6%) of group 2 and 15 (3.0%) of elderly group (P = 0.678). In-hospital complications increased with increasing age (311 [5.0%] in group 1, 235 [6.3%] in group 2, and 46 [9.3%] in elderly group; P < 0.001). Twelve-month MACE also increased with increasing age (235 [4.1%] in group 1, 169 [4.9%] in group 2 and 26 [5.7%] in elderly group; P = 0.021). Multivariate analysis showed that age was not a predictor for unsuccessful PCI, procedural complications, or 12-month MACE. However, increasing age was independent predictors of in-hospital complications and death. Despite increased in-hospital complications with increasing age, procedural success, and complications were not higher in elderly. Our data suggest that PCI should not be denied in elderly if indicated with procedural safety similar to other age groups.
- 1 March 2019
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 18 (1) , 23-31
Effect of Age on Procedural Success, Complications, and Clinical Outcome From a Large Angioplasty Registry
Increasing age appears to be a risk factor for adverse outcome in patients undergoing percutaneous coronary intervention (PCI). The goal of this study was to compare procedural success, complications, and 12 months major adverse cardiac events (MACE) based on age using a large angioplasty registry. This registry included 10,412 patients with at least 12-month follow-up from April 1993 to April 2011. Patients were divided into 3 age groups: group 1 age < 60 (n = 6195), group 2 age 60–75 (n = 3724) and group 3 elderly age ≥ 75 (n = 493). Procedural success rate was not significantly different across the 3 age groups. (96.9% in group 1, 97.1% in group 2, and 96.1% in elderly group, P = 0.759). Procedural complications occurred in 179 (2.9%) of group 1, 98 (2.6%) of group 2 and 15 (3.0%) of elderly group (P = 0.678). In-hospital complications increased with increasing age (311 [5.0%] in group 1, 235 [6.3%] in group 2, and 46 [9.3%] in elderly group; P < 0.001). Twelve-month MACE also increased with increasing age (235 [4.1%] in group 1, 169 [4.9%] in group 2 and 26 [5.7%] in elderly group; P = 0.021). Multivariate analysis showed that age was not a predictor for unsuccessful PCI, procedural complications, or 12-month MACE. However, increasing age was independent predictors of in-hospital complications and death. Despite increased in-hospital complications with increasing age, procedural success, and complications were not higher in elderly. Our data suggest that PCI should not be denied in elderly if indicated with procedural safety similar to other age groups.
- Open Access
- 27 May 2018
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 20 (6)
Sublingual Versus Oral Captopril for Decreasing Blood Pressure in Hypertension Urgency: A Randomized Clinical Trial
Background: Captopril, a short-acting antihypertensive agent, is widely used in case of emergency to control blood pressure. Although sublingual captopril has a faster onset of action, it is less tolerated. This study was performed to evaluate the efficacy, side effects, and tolerability of sublingual versus oral captopril in an emergency setting. Methods: Hypertensive patients, without acute target organ damage were randomly administered 25 mg captopril sublingually or orally (35 patients in each group). Blood pressure was measured at 0, 10, 20, 30, 45, 60, and 120 minutes after the administration. Patient satisfaction was subjectively scored on a scale of 1 - 10, and any side effect was recorded (Iranian registered clinical trials # IRCT2015110924963N1). Results: The mean age of the study groups was 59.61 ± 9.34 years. Systolic and mean blood pressure significantly decreased after 10, 20, and 30 minutes of sublingual administration (P < 0.05), but diastolic blood pressure did not decrease. This difference in the blood pressure reducing effect decreased by 60 and 90 minutes and almost equalized after 90 minutes. Headache was observed as a side effect in 2 patients in the sublingual group. The convenience and satisfaction scores were much lower in the sublingual group (6 in sublingual group versus 10 in captopril group, P < 0.001). Conclusions: In our study, the systolic and mean blood pressure decreased more rapidly in the sublingual captopril group than in the oral captopril group in the first 30 minutes after administration. Patients better tolerated the oral preparation, and the difference in the blood pressure reducing effect between the groups almost equalized after 90 minutes. Keywords: Hypertension; Captopril; Oral; Sublingual; Administration
- 27 May 2018
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 20 (6)
Open AccessSublingual Versus Oral Captopril for Decreasing Blood Pressure in Hypertension Urgency: A Randomized Clinical Trial
Background: Captopril, a short-acting antihypertensive agent, is widely used in case of emergency to control blood pressure. Although sublingual captopril has a faster onset of action, it is less tolerated. This study was performed to evaluate the efficacy, side effects, and tolerability of sublingual versus oral captopril in an emergency setting. Methods: Hypertensive patients, without acute target organ damage were randomly administered 25 mg captopril sublingually or orally (35 patients in each group). Blood pressure was measured at 0, 10, 20, 30, 45, 60, and 120 minutes after the administration. Patient satisfaction was subjectively scored on a scale of 1 - 10, and any side effect was recorded (Iranian registered clinical trials # IRCT2015110924963N1). Results: The mean age of the study groups was 59.61 ± 9.34 years. Systolic and mean blood pressure significantly decreased after 10, 20, and 30 minutes of sublingual administration (P < 0.05), but diastolic blood pressure did not decrease. This difference in the blood pressure reducing effect decreased by 60 and 90 minutes and almost equalized after 90 minutes. Headache was observed as a side effect in 2 patients in the sublingual group. The convenience and satisfaction scores were much lower in the sublingual group (6 in sublingual group versus 10 in captopril group, P < 0.001). Conclusions: In our study, the systolic and mean blood pressure decreased more rapidly in the sublingual captopril group than in the oral captopril group in the first 30 minutes after administration. Patients better tolerated the oral preparation, and the difference in the blood pressure reducing effect between the groups almost equalized after 90 minutes. Keywords: Hypertension; Captopril; Oral; Sublingual; Administration
- Open Access
- 26 June 2017
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 9 (2) , 1-7
Thiamine Supplementation in Patients with Chronic Heart Failure Receiving Optimum Medical Treatment
Background: Thiamine deficiency may cause heart failure and symptoms including edema, palpitation, tachycardia, weakness, malaise, and dyspnea due to water and salt retention and peripheral vasodilation. Patients with heart failure might be thiamine deficient and benefit thiamine supplementation. This study was designed to evaluate the effect of thiamin supplementation on some systolic and diastolic echocardiographic parameters and signs and symptoms of heart failure. Methods: Fifty two patients with systolic heart failure (LVEF < 40%) receiving optimum medical treatment, were randomized to receive 300mg thiamine or placebo for 1 month in a double-blind fashion (26 patients in each group). Echocardiographies were performed before and after treatment by a single investigator and sign and symptoms were evaluated (clinicaltrials.gov Identifier # NCT01115504). Results: Mean age was 61.44 ± 11.8 years and 67.3% were male. Maximal systolic tissue velocity of of septal and lateral walls (Sm waves) increased 0. 99 ± 1.46 and 0.83 ± 1.58 cm/s in thiamine group and changed 0.005± 1.63 and-0.1 ± 1.83 cm/s in placebo group (P = 0.033 and P = 0.044) respectievely. Ejection fraction or diastolic echocardiographic parameters were not influenced by thiamine supplementation and there was no significant effect on daily activities and dyspnea. However, peripheraledema improved in 9 patients (34.6%) of thiamine group versus 1 of the placebo group (3.8%) (P = 0.005). Conclusion: In the present study thiamine supplementation had some positive effect on edema and systolic function through an increase of lateral and septal Sm. However usefulness of routine supplementation needs more study
- 26 June 2017
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 9 (2) , 1-7
Open AccessThiamine Supplementation in Patients with Chronic Heart Failure Receiving Optimum Medical Treatment
Background: Thiamine deficiency may cause heart failure and symptoms including edema, palpitation, tachycardia, weakness, malaise, and dyspnea due to water and salt retention and peripheral vasodilation. Patients with heart failure might be thiamine deficient and benefit thiamine supplementation. This study was designed to evaluate the effect of thiamin supplementation on some systolic and diastolic echocardiographic parameters and signs and symptoms of heart failure. Methods: Fifty two patients with systolic heart failure (LVEF < 40%) receiving optimum medical treatment, were randomized to receive 300mg thiamine or placebo for 1 month in a double-blind fashion (26 patients in each group). Echocardiographies were performed before and after treatment by a single investigator and sign and symptoms were evaluated (clinicaltrials.gov Identifier # NCT01115504). Results: Mean age was 61.44 ± 11.8 years and 67.3% were male. Maximal systolic tissue velocity of of septal and lateral walls (Sm waves) increased 0. 99 ± 1.46 and 0.83 ± 1.58 cm/s in thiamine group and changed 0.005± 1.63 and-0.1 ± 1.83 cm/s in placebo group (P = 0.033 and P = 0.044) respectievely. Ejection fraction or diastolic echocardiographic parameters were not influenced by thiamine supplementation and there was no significant effect on daily activities and dyspnea. However, peripheraledema improved in 9 patients (34.6%) of thiamine group versus 1 of the placebo group (3.8%) (P = 0.005). Conclusion: In the present study thiamine supplementation had some positive effect on edema and systolic function through an increase of lateral and septal Sm. However usefulness of routine supplementation needs more study
- 5 October 2016
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 93 (2) , 214-221
Enhancement of radiosensitivity of melanoma cells by pegylated gold nanoparticles under irradiation of megavoltage electrons
Purpose: Gold nanoparticles (GNP) have significant potential as radiosensitizer agents due to their distinctive properties. Several studies have shown that the surface modification of nanoparticles with methyl polyethylene glycol (mPEG) can increase their biocompatibility. However, the present study investigated the radiosensitization effects of mPEG-coated GNP (mPEG-GNP) in B16F10 murine melanoma cells under irradiation of 6 MeV Electron beam. Materials and methods: The synthesized GNP were characterized by UV-Visible spectroscopy, dynamic light scattering, transmission electron microscopy, and zeta potential. Enhancement of radiosensitization was evaluated by the clonogenic assay at different radiation doses of megavoltage electron beams. Results: It was observed that mPEG-GNP with a hydrodynamic size of approximately 50 nm are almost spherical and cellular uptake occurred at all concentrations. Both proliferation efficiency and survival fraction decreased with increasing mPEG-GNP concentration. Furthermore, significant GNP sensitization occurred with a maximum dose enhancement factor of 1.22 at a concentration of 30 μM. Conclusions: Pegylated-GNP are taken up by B16F10 cancer cells and cause radiosensitization in the presence of 6 MeV electrons. The radiosensitization effects of GNP may probably be due to biological processes. Therefore, the underlying biological mechanisms beyond the physical dose enhancement need to be further clarified.
- 5 October 2016
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 93 (2) , 214-221
Enhancement of radiosensitivity of melanoma cells by pegylated gold nanoparticles under irradiation of megavoltage electrons
Purpose: Gold nanoparticles (GNP) have significant potential as radiosensitizer agents due to their distinctive properties. Several studies have shown that the surface modification of nanoparticles with methyl polyethylene glycol (mPEG) can increase their biocompatibility. However, the present study investigated the radiosensitization effects of mPEG-coated GNP (mPEG-GNP) in B16F10 murine melanoma cells under irradiation of 6 MeV Electron beam. Materials and methods: The synthesized GNP were characterized by UV-Visible spectroscopy, dynamic light scattering, transmission electron microscopy, and zeta potential. Enhancement of radiosensitization was evaluated by the clonogenic assay at different radiation doses of megavoltage electron beams. Results: It was observed that mPEG-GNP with a hydrodynamic size of approximately 50 nm are almost spherical and cellular uptake occurred at all concentrations. Both proliferation efficiency and survival fraction decreased with increasing mPEG-GNP concentration. Furthermore, significant GNP sensitization occurred with a maximum dose enhancement factor of 1.22 at a concentration of 30 μM. Conclusions: Pegylated-GNP are taken up by B16F10 cancer cells and cause radiosensitization in the presence of 6 MeV electrons. The radiosensitization effects of GNP may probably be due to biological processes. Therefore, the underlying biological mechanisms beyond the physical dose enhancement need to be further clarified.
- Open Access
- 14 April 2016
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 5 (4) , 1-5
General Mental Health Status of Out-Patients with Atypical Chest Pain, a Case Control Study
Objectives: Psychological problems could have some relationship with undetermined chest pain. The aim of this study was to compare the general mental health status of outpatients with atypical chest pain with a reference age and sex matched controls. Materials and methods: Patients less than 40 years old, with atypical chest pain and low probability of ischemic heart disease were included in the study. The control group were age and sex matched. The Iranian translation of 28 item general health questionnaire (GHQ-28) was used to evaluate the mental status. Results: Totally 113 cases in each group completed the study. Mean age of the study group was 26.33 ± 5.77years and 148 cases (65.5%) were female. Mean GHQ-28 score in the atypical chest pain and the control groups were 31.37±14.69 and 21.31±9.97 respectively (P<0.001). Abnormal GHQ-28 scores (≥24) was seen in 71(62.8%) of the atypical chest pain group and 38(33.6%) of the controls (odds ratio: 3.34, 95% confidence interval =1.93-5.76). Multivariate analysis showed that after adjustment for possible confounding factors, atypical chest pain was an independent predictor of abnormal GHQ-28(odds ratio: 3.32, 95% confidence interval: 1.31-8.47). Discussion: The results of the present study showed that our patients with atypical chest pain had worse general mental health state. It is not clear that worse general health state is a cause of atypical chest pain or an incidental concomitant finding.
- 14 April 2016
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 5 (4) , 1-5
Open AccessGeneral Mental Health Status of Out-Patients with Atypical Chest Pain, a Case Control Study
Objectives: Psychological problems could have some relationship with undetermined chest pain. The aim of this study was to compare the general mental health status of outpatients with atypical chest pain with a reference age and sex matched controls. Materials and methods: Patients less than 40 years old, with atypical chest pain and low probability of ischemic heart disease were included in the study. The control group were age and sex matched. The Iranian translation of 28 item general health questionnaire (GHQ-28) was used to evaluate the mental status. Results: Totally 113 cases in each group completed the study. Mean age of the study group was 26.33 ± 5.77years and 148 cases (65.5%) were female. Mean GHQ-28 score in the atypical chest pain and the control groups were 31.37±14.69 and 21.31±9.97 respectively (P<0.001). Abnormal GHQ-28 scores (≥24) was seen in 71(62.8%) of the atypical chest pain group and 38(33.6%) of the controls (odds ratio: 3.34, 95% confidence interval =1.93-5.76). Multivariate analysis showed that after adjustment for possible confounding factors, atypical chest pain was an independent predictor of abnormal GHQ-28(odds ratio: 3.32, 95% confidence interval: 1.31-8.47). Discussion: The results of the present study showed that our patients with atypical chest pain had worse general mental health state. It is not clear that worse general health state is a cause of atypical chest pain or an incidental concomitant finding.
- Open Access
- 14 May 2015
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 2 (6) , 1-8
ST Elevation in Lead aVR and In-Hospital and Mid-Term Adverse Events in Patients with Medically Treated ST Elevation Myocardial Infarction
Background: ST segment elevation and deviation in lead aVR can provide useful prognostic information in patients with ST elevation myocardial infarction (STEMI). The aim of the present study was evaluation of the effect of aVR ST elevation (aVR-STE) and aVR ST deviation (aVR-STD) the in-hospital and sixmonth prognosis of patients with STEMI. Methods: The study was a cohort of medically treated patients with acute STEMI. The patients were categorized as aVR ST elevation (aVR-STE) or aVR ST deviation (aVR-STD) if there was > 0.05 mv ST elevation or ST deviation in lead aVR, respectively; otherwise, they were categorized as control groups. Results: 334 patients [49 patients (14.67%) with aVR-STE and 159 patients (47.60%) with aVR-STD] were included. The mean age of the study group was 59.62 ± 13.03 years and 75.4% were male. In-hospital mortality was not significantly different in patients with or without aVR-STE or aVR-STD. Pulmonary edema or overt decompensated heart failure was seen more in patients with aVR-STE [Relative risk (RR): 3.393, 95% confidence interval: 1.405-8.192, P = 0.012] and it trended more in patients with aVR-STD (P = 0.06).
- 14 May 2015
- Published by MedCrave Group Kft. in Journal of Cardiology & Current Research
- Vol. 2 (6) , 1-8
Open AccessST Elevation in Lead aVR and In-Hospital and Mid-Term Adverse Events in Patients with Medically Treated ST Elevation Myocardial Infarction
Background: ST segment elevation and deviation in lead aVR can provide useful prognostic information in patients with ST elevation myocardial infarction (STEMI). The aim of the present study was evaluation of the effect of aVR ST elevation (aVR-STE) and aVR ST deviation (aVR-STD) the in-hospital and sixmonth prognosis of patients with STEMI. Methods: The study was a cohort of medically treated patients with acute STEMI. The patients were categorized as aVR ST elevation (aVR-STE) or aVR ST deviation (aVR-STD) if there was > 0.05 mv ST elevation or ST deviation in lead aVR, respectively; otherwise, they were categorized as control groups. Results: 334 patients [49 patients (14.67%) with aVR-STE and 159 patients (47.60%) with aVR-STD] were included. The mean age of the study group was 59.62 ± 13.03 years and 75.4% were male. In-hospital mortality was not significantly different in patients with or without aVR-STE or aVR-STD. Pulmonary edema or overt decompensated heart failure was seen more in patients with aVR-STE [Relative risk (RR): 3.393, 95% confidence interval: 1.405-8.192, P = 0.012] and it trended more in patients with aVR-STD (P = 0.06).
- Open Access
- 8 December 2014
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 16 (12) , e7887
Ramadan Fast in Patients With Coronary Artery Disease
Background: Fasting during the month of Ramadan is of vital significance amongst Muslims; however, little is known about the effects of this kind of fasting on patients with coronary artery disease (CAD). Objectives: This nonrandomized prospective observational pilot study was designed to investigate the effects of Ramadan fast on the symptoms of CAD. Patients and Methods: Patients with documented CAD were consecutively (nonrandomized) included in the study, and those with heart failure (ejection fraction < 50%), renal failure, gout, and insulin-treated diabetes were excluded. Patients had the choice of fasting during Ramadan if they so wished and to break their fast as soon as symptoms such as dyspnea and chest pain occurred (fasting group) or not fasting (control group). Results: A total of 148 patients completed the study. Mean (mean ± SD) age of the patients was 61.5 ± 11.7 years and 50% were male. Finally, 66 patients (44.6%) accomplished Ramadan fast with an average of 22.27 ± 10.46 days of fasting. Occurrence of chest pain was not significantly different between the fasting and non-fasting groups (4 out of 66 [6.1%] vs. 8 out of 82 [9.8%] respectively; P = 0.42). In addition, patients who fasted during Ramadan did not experience a higher frequency of a combined endpoint of chest pain and dyspnea (4 out of 66 cases in the fasting group [6.1%] vs. 11 out of 82 in non-fasting group [13.4%]; P = 0.14). Conclusions: In the present study, the patients with CAD were able to observe Ramadan fast safely and their combined endpoint of chest pain and dyspnea was not significantly different from that of the non-fasting ones. We would suggest that patients with CAD and normal left ventricular function could fast during Ramadan. Keywords: Fasting; Coronary Artery Disease; Ramadan; Chest Pain; Dyspnea
- 8 December 2014
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 16 (12) , e7887
Open AccessRamadan Fast in Patients With Coronary Artery Disease
Background: Fasting during the month of Ramadan is of vital significance amongst Muslims; however, little is known about the effects of this kind of fasting on patients with coronary artery disease (CAD). Objectives: This nonrandomized prospective observational pilot study was designed to investigate the effects of Ramadan fast on the symptoms of CAD. Patients and Methods: Patients with documented CAD were consecutively (nonrandomized) included in the study, and those with heart failure (ejection fraction < 50%), renal failure, gout, and insulin-treated diabetes were excluded. Patients had the choice of fasting during Ramadan if they so wished and to break their fast as soon as symptoms such as dyspnea and chest pain occurred (fasting group) or not fasting (control group). Results: A total of 148 patients completed the study. Mean (mean ± SD) age of the patients was 61.5 ± 11.7 years and 50% were male. Finally, 66 patients (44.6%) accomplished Ramadan fast with an average of 22.27 ± 10.46 days of fasting. Occurrence of chest pain was not significantly different between the fasting and non-fasting groups (4 out of 66 [6.1%] vs. 8 out of 82 [9.8%] respectively; P = 0.42). In addition, patients who fasted during Ramadan did not experience a higher frequency of a combined endpoint of chest pain and dyspnea (4 out of 66 cases in the fasting group [6.1%] vs. 11 out of 82 in non-fasting group [13.4%]; P = 0.14). Conclusions: In the present study, the patients with CAD were able to observe Ramadan fast safely and their combined endpoint of chest pain and dyspnea was not significantly different from that of the non-fasting ones. We would suggest that patients with CAD and normal left ventricular function could fast during Ramadan. Keywords: Fasting; Coronary Artery Disease; Ramadan; Chest Pain; Dyspnea